MX2024004355A - Tratamiento de la enfermedad renal. - Google Patents
Tratamiento de la enfermedad renal.Info
- Publication number
- MX2024004355A MX2024004355A MX2024004355A MX2024004355A MX2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney disease
- treatment
- therapeutic
- kidney function
- kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Abstract
En el presente documento se proporciona el uso de un agente terapéutico de células renales autólogas, por ejemplo, seleccionadas, para mejorar la función renal de un paciente humano que tiene enfermedad renal crónica diabética. El uso del terapéutico, administrado en la primera y segunda inyecciones, aumenta la función renal del paciente, por ejemplo, la tasa de filtración glomerular estimada, en el transcurso de al menos un año y estabiliza otros parámetros clínicos que disminuyen durante la enfermedad renal.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255885P | 2021-10-14 | 2021-10-14 | |
| US202263307801P | 2022-02-08 | 2022-02-08 | |
| US202263321204P | 2022-03-18 | 2022-03-18 | |
| PCT/US2022/078153 WO2023064925A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004355A true MX2024004355A (es) | 2024-06-21 |
Family
ID=85988933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004355A MX2024004355A (es) | 2021-10-14 | 2022-10-14 | Tratamiento de la enfermedad renal. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250009803A1 (es) |
| EP (1) | EP4415729A4 (es) |
| JP (1) | JP2024536479A (es) |
| KR (1) | KR20240110801A (es) |
| AU (1) | AU2022362077A1 (es) |
| CA (1) | CA3233866A1 (es) |
| MX (1) | MX2024004355A (es) |
| WO (1) | WO2023064925A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106530A1 (en) * | 2023-11-13 | 2025-05-22 | Butler Emily | Characteristics of enriched heterogeneous renal cell populations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020223660A1 (en) * | 2019-05-02 | 2020-11-05 | Timothy Bertram | Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies |
-
2022
- 2022-10-14 KR KR1020247015819A patent/KR20240110801A/ko active Pending
- 2022-10-14 JP JP2024522027A patent/JP2024536479A/ja active Pending
- 2022-10-14 EP EP22882059.3A patent/EP4415729A4/en active Pending
- 2022-10-14 CA CA3233866A patent/CA3233866A1/en active Pending
- 2022-10-14 WO PCT/US2022/078153 patent/WO2023064925A1/en not_active Ceased
- 2022-10-14 MX MX2024004355A patent/MX2024004355A/es unknown
- 2022-10-14 US US18/699,849 patent/US20250009803A1/en active Pending
- 2022-10-14 AU AU2022362077A patent/AU2022362077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064925A1 (en) | 2023-04-20 |
| CA3233866A1 (en) | 2023-04-20 |
| AU2022362077A1 (en) | 2024-05-02 |
| JP2024536479A (ja) | 2024-10-04 |
| WO2023064925A8 (en) | 2024-04-11 |
| EP4415729A1 (en) | 2024-08-21 |
| EP4415729A4 (en) | 2025-08-27 |
| US20250009803A1 (en) | 2025-01-09 |
| KR20240110801A (ko) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008109238A (ru) | Способы лечения заболеваний антагонистами vegf | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| NZ596041A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
| RU2008141076A (ru) | Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами | |
| Gil et al. | Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients | |
| Santoro et al. | Vascular access for hemodialysis | |
| Hayes et al. | Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report | |
| Qu et al. | Priapism secondary to chronic myeloid leukemia treated by a surgical cavernosa-corpus spongiosum shunt: Case report | |
| MX2024004355A (es) | Tratamiento de la enfermedad renal. | |
| CA2574450A1 (en) | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| CN104307064B (zh) | 一种肢体局部给药和透析装置及其应用 | |
| RU2014150946A (ru) | Способ снижения веса | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| Donati et al. | Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report | |
| RU2483723C1 (ru) | Способ лечения эндокринной офтальмопатии | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| MX2024005374A (es) | Metodos para tratar la enfermedad de celulas falciformes con voxelotor. | |
| DE202012100195U1 (de) | Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod | |
| CN205586290U (zh) | 一种水筋针治疗系统 | |
| CN109453191A (zh) | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 | |
| EA202192612A1 (ru) | Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| WO2007011960A3 (en) | Methods and agents to treat autoimmune diseases | |
| Crombie et al. | 837 Impact of Autologous, Non-Autologous, Synthetic Tissue Substitutes in Burns 2016-2021: Analysis of National Burn Repository |